Aytu BioPharma Announces $12.9M Public Offering

The latest announcement is out from Aytu BioScience ( (AYTU) ).

On June 5, 2025, Aytu BioPharma announced an underwriting agreement with Lake Street Capital Markets for a public offering of common stock and prefunded warrants, aiming to raise approximately $12.9 million. The proceeds will be used for general corporate purposes and to commercialize EXXUA™ (gepirone) extended-release tablets. The offering, expected to close around June 9, 2025, is part of Aytu’s strategy to strengthen its market position in novel therapeutics for major depressive disorder.

The most recent analyst rating on (AYTU) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Aytu BioScience stock, see the AYTU Stock Forecast page.

Spark’s Take on AYTU Stock

According to Spark, TipRanks’ AI Analyst, AYTU is a Neutral.

The overall score reflects strong earnings call outcomes with significant revenue growth and operational improvements, but is weighed down by ongoing profitability challenges and negative cash flow. Technical analysis provides mixed signals, while valuation challenges persist due to a negative P/E ratio and lack of dividends.

To see Spark’s full report on AYTU stock, click here.

More about Aytu BioScience

Aytu BioPharma is a pharmaceutical company focused on commercializing novel therapeutics. Its prescription products include EXXUA™ (gepirone) extended-release tablets for major depressive disorder, Adzenys XR-ODT® and Cotempla XR-ODT® for attention deficit hyperactivity disorder, and a line of legacy products such as Karbinal® ER, Poly-Vi-Flor®, and Tri-Vi-Flor®.

Average Trading Volume: 1,208,108

Technical Sentiment Signal: Sell

Current Market Cap: $9.81M

Find detailed analytics on AYTU stock on TipRanks’ Stock Analysis page.